Trevi Therapeutics (NASDAQ:TRVI) Receives New Coverage From Analysts at SVB Leerink
Trevi Therapeutics (NASDAQ:TRVI) Receives New Coverage From Analysts at SVB Leerink
SVB Leerink assumed coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Get Rating) in a report released on Tuesday, MarketBeat Ratings reports. The firm issued an outperform rating and a $6.00 target price on the stock.
據MarketBeat Ratings報道，SVB Leerink在週二發佈的一份報告中對特雷維治療公司(納斯達克：TRVI-GET Rating)的股票進行了報道。該公司對該股發佈了跑贏大盤的評級和6.00美元的目標價。
TRVI has been the subject of several other research reports. Oppenheimer decreased their price target on Trevi Therapeutics to $9.00 in a research note on Thursday, November 17th. Needham & Company LLC reduced their target price on Trevi Therapeutics from $10.00 to $8.00 and set a buy rating for the company in a report on Friday, November 11th.
TRVI一直是其他幾份研究報告的主題。奧本海默在11月17日星期四的一份研究報告中將他們對Trevi治療公司的目標價下調至9.00美元。Needham&Company LLC將Trevi治療公司的目標價從10.00美元下調至8.00美元，並在11月11日星期五的一份報告中為該公司設定了買入評級。
Trevi Therapeutics Price Performance
特雷維治療公司性價比
NASDAQ TRVI opened at $1.87 on Tuesday. The company has a quick ratio of 8.70, a current ratio of 8.70 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $112.06 million, a PE ratio of -2.40 and a beta of 0.75. Trevi Therapeutics has a 12-month low of $0.46 and a 12-month high of $4.68. The company has a 50 day moving average price of $2.01 and a two-hundred day moving average price of $2.64.
納斯達克週二開盤報1.87美元。該公司的速動比率為8.70，流動比率為8.70，債務權益比率為0.03。該股市值為1.1206億美元，市盈率為-2.40，貝塔係數為0.75。Trevi Treeutics的12個月低點為0.46美元，12個月高位為4.68美元。該公司的50日移動均線價格為2.01美元，200日移動均線價格為2.64美元。
Institutional Investors Weigh In On Trevi Therapeutics
機構投資者看好特雷維治療公司
A number of hedge funds have recently bought and sold shares of TRVI. State Street Corp increased its stake in shares of Trevi Therapeutics by 93.4% in the third quarter. State Street Corp now owns 77,042 shares of the company's stock worth $119,000 after purchasing an additional 37,200 shares during the period. Two Sigma Investments LP acquired a new stake in Trevi Therapeutics in the 3rd quarter valued at approximately $122,000. Vanguard Group Inc. grew its holdings in Trevi Therapeutics by 459.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,324,377 shares of the company's stock valued at $2,040,000 after buying an additional 1,087,437 shares during the last quarter. Marshall Wace LLP bought a new position in Trevi Therapeutics in the 3rd quarter worth approximately $198,000. Finally, Armistice Capital LLC lifted its holdings in shares of Trevi Therapeutics by 107.7% during the third quarter. Armistice Capital LLC now owns 864,000 shares of the company's stock worth $1,331,000 after buying an additional 448,000 shares during the last quarter.
多家對衝基金最近買賣了TRVI的股票。道富集團第三季度增持Trevi Treeutics股票93.4%。道富銀行目前持有77,042股該公司股票，價值119,000美元，在此期間又購買了37,200股。Two Sigma Investments LP在第三季度收購了Trevi Treeutics的新股份，價值約為12.2萬美元。先鋒集團在第三季度增持了459.0%的特雷維治療公司的股份。先鋒集團目前持有1,324,377股該公司股票，價值2,040,000美元，上一季度又購買了1,087,437股。馬歇爾·華斯有限責任公司在第三季度購買了特雷維治療公司的一個新頭寸，價值約19.8萬美元。最後，停戰資本有限責任公司在第三季度增持了特雷維治療公司的股票107.7%。停戰資本有限責任公司現在擁有864,000股該公司的股票，價值1,331,000美元，在上個季度又購買了448,000股。
Trevi Therapeutics Company Profile
特雷維治療公司簡介
(Get Rating)
(獲取評級)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
Trevi治療公司是一家臨牀階段的生物製藥公司，專注於Haduvio的開發和商業化，以治療嚴重的神經介導性疾病。該公司正在開發Haduvio，這是一種納布芬的口服緩釋製劑，處於IIb/III期臨牀試驗，用於治療特發性肺纖維化患者的慢性瘙癢和慢性咳嗽。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick's Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
- 免費獲取StockNews.com關於特雷維治療公司(TRVI)的研究報告
- 在取消了13%的股息後，Lumen Technologies可以擁有嗎？
- 思科希望重組削減成本以增加收入
- Dick‘s體育用品的賣方上限收益
- 炒股：3只有吸引力的股票，交易價格在10美元左右
- 想要獲得10%的股息收益率，看看這裏
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Trevi治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Trevi治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。